GSK sells off stake in Aspen for $853m
March 13, 2015Sales and Marketing Africa, China, GSK, Novartis, Singapore, aspen, merger, redfern
GlaxoSmithKline has sold off half its stake in South Africa’s Aspen Pharmacare in a move that will net the British …
Takeda gets NICE nod for bowel treatment
March 13, 2015Sales and Marketing NHS, NICE, Takeda, enyyvio, vedolizumab
Takeda’s Entyvio becomes the first NICE approved gut-selective treatment for UK patients with ulcerative colitis (UC) – a long-term condition …
AXON Communications adds five to London team
March 13, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Axon, bilotta, burns, peregrin, treadwell, ura
UK healthcare comms and PR firm AXON Communications has added five new members to its team in London. Lucie Burns …
J&J pleads guilty over children’s contaminated medicine
March 12, 2015Manufacturing and Production, Sales and Marketing FDA, J&J, JJ, McNeil, OTC, Tylenol, consta, hamburg, recall
Johnson & Johnson’s consumer division McNeil has pleaded guilty and will pay fines of $25 million for wrongdoings regarding its …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
Endo attempts to outbid Valeant for Salix Pharma
March 12, 2015Sales and Marketing Endo, Valeant, merger, outbid, pharma, salix
Endo has joined the race for Salix, the firm that Valeant reached a $14.5 billion agreement to purchase last month. …
GSK picks Singapore for Asian hub
March 12, 2015Manufacturing and Production, Research and Development, Sales and Marketing Asia, GSK, Singapore, Takeda, Witty, emerging markets
Despite GlaxoSmithKline’s ongoing troubles in Asia it has decided to establish a new HQ in Singapore to bolster its presence …
UCB sponsors ‘Hack Epilepsy’ digital event
March 12, 2015Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat
Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …
Adaptimmune appoints PwC head to board
March 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lawrence Alleva, adaptimune, pwC
Clinical-stage biotech firm Adaptimmune has appointed Lawrence Alleva as a non-executive director who is also to serve as chairman of its …
Merck’s cancer drug sees first ever early access nod
March 11, 2015Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab
Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …
Merck Serono bets on precision medicine
March 11, 2015Sales and Marketing AstraZeneca, Diagnostics, FDA, Illumina, Merck Serono, opexa, personalised
Merck Serono is looking to expand further into personalised medicine as the company enters into an agreement with Illumina to …
GSK China scandal leads to staff conflict
March 11, 2015Sales and Marketing China, GSK, GlaxoSmithKline, bribery, chinese, cuts, sacked
Around 135 workers who face being removed from their posts by GlaxoSmithKline due to misconduct centering on bribery scandals in …
Government pledges ‘new era’ for NHS
March 11, 2015Research and Development, Sales and Marketing NHS, Simon Stevens, five year, reform, reorganisation, vanguard
The government is investing £200 million to back healthcare professionals to implement their own ideas for improving patient care. The …
New details of Innovative Medicines review disclosed
March 11, 2015Research and Development, Sales and Marketing ABPI, NHS, NICE, PPRS, UK, george freeman, innovative medicines
The government has announced details of a sweeping review into how medicines are accessed in the UK. The Innovative Medicines …
NICE approves Roche’s Gazyvaro and Novartis’ Xolair
March 11, 2015Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab
NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …
New head of digital for Virgo Health
March 11, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Virgo HEALTH, tom griffiths
UK-based healthcare comms agency Virgo Health has increased its leadership team through the appointment of Tom Griffiths as head of digital. …
HRT pills linked to increase in clots and strokes
March 10, 2015Research and Development, Sales and Marketing Cochrane, HRT, boardman, hormone replacement therapy
HRT tablets do not offer heart benefits and slightly increase the risk of strokes and blood clots in some women. …
German court rules against Lilly in Alimta patent case
March 10, 2015Manufacturing and Production, Sales and Marketing ACS, Actavis, Alimta, NICE, NSCLC, lilly, lung cancer, pemetrexed
A German court has ruled that Lilly’s patent for its lung cancer drug Alimta would not be infringed by generic …
$10 generic Solvaldi emerges in Bangladesh
March 10, 2015Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
FDA gives new safety warning on Pfizer’s Champix
March 10, 2015Manufacturing and Production, Sales and Marketing Champix, Cochrane, FDA, MHRA, Pfizer, varenicline
The FDA has warned that Pfizer’s stop smoking drug Champix is linked with seizures, aggressive behaviour and blackouts. In its …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
